Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo is a research paper published in The Journal of Infectious Diseases (2023). On theSindex it has a DataRank of 0.390. It has been cited 9 times, with 7 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.345
From this paper's citation signal
Citation Network Contribution
0.0442
From 4 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 7 citers.
National Institutes of Health
Grant: HHSN272200800003C
National Institutes of Health
Grant: HHSN272201300021I
National Institutes of Health
Grant: HHSN272200800005C
National Institutes of Health
Grant: HHSN272201300018I
National Institutes of Health
Grant: HHSN272200800013C
National Institutes of Health
Grant: 75N93021C00012
NIAID NIH HHS
Grant: UM1 AI148685
NIAID NIH HHS
Grant: P30 AI168386
Fields of Study
MeSH Terms
Keywords